CA2576576A1 - Arn interferant specifique vis-a-vis de la gastrine - Google Patents

Arn interferant specifique vis-a-vis de la gastrine Download PDF

Info

Publication number
CA2576576A1
CA2576576A1 CA002576576A CA2576576A CA2576576A1 CA 2576576 A1 CA2576576 A1 CA 2576576A1 CA 002576576 A CA002576576 A CA 002576576A CA 2576576 A CA2576576 A CA 2576576A CA 2576576 A1 CA2576576 A1 CA 2576576A1
Authority
CA
Canada
Prior art keywords
gastrin
rnai
gene
ribonucleic acid
gastrin gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002576576A
Other languages
English (en)
Inventor
Susan A. Watson
Anna Grabowska
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Receptor Biologix Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2576576A1 publication Critical patent/CA2576576A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/595—Gastrins; Cholecystokinins [CCK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3517—Marker; Tag
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002576576A 2004-08-11 2005-08-10 Arn interferant specifique vis-a-vis de la gastrine Abandoned CA2576576A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US60069604P 2004-08-11 2004-08-11
US60/600,696 2004-08-11
PCT/IB2005/002686 WO2006016275A2 (fr) 2004-08-11 2005-08-10 Arn interférant spécifique vis-à-vis de la gastrine

Publications (1)

Publication Number Publication Date
CA2576576A1 true CA2576576A1 (fr) 2006-02-16

Family

ID=35759261

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002576576A Abandoned CA2576576A1 (fr) 2004-08-11 2005-08-10 Arn interferant specifique vis-a-vis de la gastrine

Country Status (5)

Country Link
EP (1) EP1778841A2 (fr)
KR (1) KR20070062515A (fr)
AU (1) AU2005270917A1 (fr)
CA (1) CA2576576A1 (fr)
WO (1) WO2006016275A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004225437B2 (en) 2003-03-28 2010-05-13 Cancer Advances, Inc. Gastrin hormone immunoassays
US8889640B1 (en) * 2008-06-20 2014-11-18 Jill P. Smith Composition and method for the treatment of gastrin mediated cancers
US11583576B2 (en) 2017-06-15 2023-02-21 Cancer Advances Inc. Compositions and methods for inducing humoral and cellular immunities against tumors and cancer
CN117062621A (zh) * 2021-01-13 2023-11-14 癌症进展有限公司 用于预防肿瘤和癌症的组合物和方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2936534C (fr) * 2001-07-23 2021-01-26 The Board Of Trustees Of Leland Stanford Junior University Methodes et compositions pour l'inhibition induite par l'arni de l'expression genetique chez des mammiferes
AU2003283374A1 (en) * 2002-11-08 2004-06-07 Klaus Strebhardt Pharmaceutical composition for suppressing undesired gene expression

Also Published As

Publication number Publication date
WO2006016275A3 (fr) 2006-05-18
WO2006016275A2 (fr) 2006-02-16
EP1778841A2 (fr) 2007-05-02
AU2005270917A8 (en) 2006-02-16
KR20070062515A (ko) 2007-06-15
AU2005270917A1 (en) 2006-02-16

Similar Documents

Publication Publication Date Title
US9074205B2 (en) Nicked or gapped nucleic acid molecules and uses thereof
US9695425B2 (en) RNA aptamers against BAFF-R as cell-type specific delivery agents and methods for their use
KR101605932B1 (ko) Ｈｓｆ1-관련 질환을 치료하기 위한 유기 조성물
CN113164509A (zh) 用于抑制17β-HSD 13型(HSD17B13)表达的RNAi试剂、其组合物和使用方法
US20100047909A1 (en) Nucleic acid compounds for inhibiting vegf family gene expression and uses thereof
US20080287383A1 (en) Nucleic acid compounds for inhibiting erbb gene expression and uses thereof
WO2019196887A1 (fr) Nouveau petit arn activateur
US20100112687A1 (en) Nucleic acid compounds for inhibiting erbb family gene expression and uses thereof
KR20110017005A (ko) Ｔｇｆ-베타 수용체 유전자 발현 억제용 조성물 및 방법
US20080286866A1 (en) Nucleic acid compounds for inhibiting vegf gene expression and uses thereof
KR20220069103A (ko) 최소 플루오린 함량을 갖는 작은 간섭 rna의 화학적 변형
US20100055782A1 (en) Nucleic acid compounds for inhibiting myc gene expression and uses thereof
JP6882735B2 (ja) 構造強化されたｍｉＲＮＡ阻害剤Ｓ−ＴｕＤ
CA2576576A1 (fr) Arn interferant specifique vis-a-vis de la gastrine
WO2008109366A2 (fr) Composés d'acide nucléique permettant d'inhiber l'expression de gène ccnd1 et utilisations de ceux-ci
JP2022541212A (ja) 治療的使用のための、ヒト遺伝子ＪＡＫ１又はＪＡＫ３の発現を標的とするＳｉＲＮＡ配列
WO2021039598A1 (fr) Inhibiteur de l'action de l'arn et son utilisation
WO2008109359A1 (fr) Composés d'acide nucléique permettant d'inhiber l'expression de gène de la famille pdgfr et utilisations de ceux-ci
Gutierrez Aguirregabiria Using synthetic oligonucleotides to modify cellular IRES structures and control gene expression
WO2012131673A2 (fr) Agents de type acides nucléiques inactivant le ccat-1 pour traiter le cancer
WO2022256354A1 (fr) Adn duplex court en tant que nouvelle technologie d'inactivation de gènes et utilisation de celle-ci
CN114829601A (zh) Sbds抑制剂用于治疗乙型肝炎病毒感染的用途
AU2016204462A1 (en) Nicked or gapped nucleic acid molecules and uses thereof
AU2014200144A1 (en) Nicked or gapped nucleic acid molecules and uses thereof
WO2008109380A2 (fr) Composés d'acide nucléique pour inhiber l'expression du gène de la famille vegfr et utilisations de ceux-ci

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued